Evotec consensus picture on Nasdaq EVO, shares hover around 2.74 dollars
28.06.2026 - 12:58:02 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 12:57.
Evotec (DE0005664809) sits in focus at the start of the week with its Nasdaq listing under the ticker EVO. The latest available closing price on Nasdaq for Evotec shares stands at 2.74 to 2.76 US dollars, highlighting the current level for the ADR as of June 26, 2026 according to TradingKey and MarketBeat.TradingKey ownership data for Evotec EVO
What ownership data shows
Evotec’s Nasdaq EVO listing gives a detailed view of institutional holdings and market capitalization. TradingKey reports a market cap of around 993.36 million US dollars for Evotec based on the June 26 close, providing a transparent size marker for the biotech.TradingKey market cap and holdings overview
The same source cites a closing price of 2.74 to 2.76 US dollars for the EVO shares on June 26, 2026, with after-hours trading indicated at 0.00 change, reflecting muted short-term volatility.MarketBeat latest EVO quote and news
Analyst and consensus angle
On the Nasdaq listing, consensus and coverage help frame expectations for Evotec as a mid-cap biotech. MarketBeat aggregates recent EVO news and price data, showing the closing price at 2.76 US dollars on June 26, 2026 and a slight 1.66 percent move on that day.MarketBeat EVO news and performance summary
With a near-billion-dollar market cap and an ADR price below three dollars, Evotec’s Nasdaq EVO profile combines biotech exposure with small-ticket share pricing, a structure often noted in analyst and market commentary for retail investors tracking international healthcare names.TradingKey institutional and ADR structure details
All news and analysis on the Evotec shares
Further ad-hoc-news coverage and Evotec’s own investor relations material provide additional detail on guidance, pipeline and capital-market events behind the EVO listing.
The business behind Evotec
Evotec is a drug discovery and development company, working with pharmaceutical partners on early-stage research and clinical candidates. A core business line is its integrated discovery and development platform, which supports external partners in identifying and advancing new therapeutic molecules in areas such as neurology and metabolic diseases.Evotec investor relations overview of business segments
Where the EVO listing trades
The Evotec shares (DE0005664809) trade in the United States as Nasdaq-listed ADRs under the ticker EVO, with the latest closing price on June 26, 2026 at 2.76 US dollars and a market capitalization around 993 million US dollars based on TradingKey data.TradingKey latest EVO price and market cap
Key data on the Evotec shares
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVO
- Trading venue: Nasdaq (ADR)
- Price (as of 2026-06-26, 16:00): 2.76 US dollars
- Market cap: 993.36 million US dollars (as of 2026-06-26)
- Sector / industry: Biotechnology / Life Sciences Tools & Services
- Index membership: Not a member of major US indices such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or a solicitation to buy or sell any financial instrument. All data are based on sources cited and may change; investors should consult original filings and professional advisers before making investment decisions.
